To compare the risk of hospitalization between patients with early-stage breast cancer who received different chemotherapy regimens.
INTRODUCTION
In patients with early-stage breast cancer, chemotherapy reduces recurrence and mortality rates and improves survival rates. 1 Anthracyclines are effective drugs, but they infrequently cause congestive heart failure (approximately 2% of patients). [2] [3] [4] Anthracyclines have also been associated with secondary leukemia. [5] [6] [7] [8] Therefore, equally effective nonanthracycline-based regimens have been sought. In the United States, the use of anthracyclines has decreased, whereas the use of taxanebased regimens without an anthracycline has increased. 9 This shift was likely influenced by studies initially presented in December of 2005 that suggested that taxane-based regimens without anthra-cycline might provide equivalent or superior results to anthracycline-based regimens. 10, 11 There is no evidence that taxane-based regimens without an anthracycline are superior to thirdgeneration regimens that combine an anthracycline with a taxane. A phase III randomized clinical trial showed that the disease-free survival and overall survival of patients who received four cycles of docetaxel and cyclophosphamide was higher than that of patients who received four cycles of doxorubicin and cyclophosphamide, a first-generation anthracycline-based regimen. 12, 13 A phase III clinical trial comparing docetaxel and cyclophosphamide with a third-generation anthracycline/ taxane regimen is ongoing. 14 with taxanes in the adjuvant treatment of breast cancer is insufficient, and the optimal chemotherapy regimen in this setting remains unknown. 15, 16 Several chemotherapy regimens 17 are available to patients diagnosed with early-stage breast cancer. Characterizing subsets of patients who are at the greatest risk for developing toxicities may help guide clinicians in the choice of a regimen. Given the uncertainty surrounding the optimal chemotherapy regimen for this disease, the toxicities of each regimen become more relevant when selecting therapy. No population-based studies have compared the toxicities of specific chemotherapy regimens.
In the present study, we used claims-based data to compare the risk of chemotherapy-related hospitalization between patients with early-stage breast cancer identified in two databases who received commonly used chemotherapy regimens.
PATIENTS AND METHODS

Data Sources
We identified patients older than age 65 years from the SEER/Texas Cancer Registry (TCR) -Medicare-linked database 18, 19 and patients younger than age 65 years from the MarketScan database. 20 The TCR, 21 which was legislatively mandated in 1979 as a component of the Texas Department of State Health Services, is the fourth largest state population-based registry. Annually, it receives approximately 250,000 reports of cancer cases from diverse clinical sources and other state registries. Vital status and cause of death information is obtained through data linkages with Texas vital statistics and mortality data, the National Death Index, and the Social Security Death Index. The TCR meets the high-quality data standards of the Centers for Disease Control and Prevention's National Program of Cancer Registries and has a Gold Standard for Registry Certification from the North American Association of Central Cancer Registries. The TCR collects data according to standardized registry rules and has core data items similar to those collected by the SEER registries.
The SEER registries provide information on approximately 25% of the nation's incident cancers and have been linked to Medicare claims. 18, 19 The details of the SEER-Medicare linked database have been previously published. 22 The National Cancer Institute has also linked TCR data to Medicare claims, using the same standards and algorithms used to create the SEER-Medicare linkage. For the analyses in the present study, the TCR-Medicare and SEER-Medicare data sets were combined.
The MarketScan 20 database consists of proprietary data sets that meet Health Insurance Portability and Accountability Act requirements for confidentiality, and undergoes quality validity checks. Files are released once 100% of the claims have been paid. In the present study, we used the Commercial Claims and Encounters data set, a large nationwide employment-based database that contains information about medical claims and outpatient prescription claims paid on behalf of employees and their dependents. The data set is considered a convenience sample that includes a younger population, covers a comprehensive geographic area, and contains demographic and comorbidity data from nationwide private medical insurance claims.
Study Population
From the SEER/TCR-Medicare linked database, we identified patients older than age 65 years who received a first diagnosis of stage I, II, or III breast cancer (identified using the International Classification of Diseases, ninth revision, and Current Procedural Terminology codes in Appendix Table A1 ; online only) between 2003 and 2007 and underwent lumpectomy, mastectomy, or axillary lymph node dissection. To ensure data completeness, we included only patients who had full medical insurance coverage provided by Medicare Part A and Part B during the 12 months before and after diagnosis and had not been Health Maintenance Organization members. Patients with a prior diagnosis of any other cancer were excluded. Of the 52,838 patients we identified, 10,921 had received chemotherapy; of these patients, 3,567 had received 1 of the 6 regimens described below.
From the MarketScan database, using an algorithm 9 adapted from previously described algorithms, 23-26 we identified patients age less than 65 years who received a first diagnosis of breast cancer between 2003 and 2007, and underwent lumpectomy, mastectomy, or axillary lymph node dissection. We included patients who had continuous medical insurance coverage during the 3 months before and 12 months after diagnosis. Of the 47,050 patients we identified, 21,833 received chemotherapy; of these patients, 9,327 had received 1 of the 6 regimens described below. The regimens received by the patients identified from either database who were excluded from the present study are given in Appendix Table A2 (online only) .
Study Variables
Chemotherapy regimens. We used Healthcare Common Procedure Coding System codes for chemotherapy drugs ("J" codes) 27-30 to identify patient's chemotherapy regimens (Appendix Table A3 , online only). We selected only patients who received chemotherapy within 3 months before and 12 months after the date of diagnosis (SEER/TCR-Medicare) or the date of surgery (MarketScan). We then categorized patients into 1 of 6 groups according to the specific chemotherapy regimen they received. Patients had to have received at least 2 consecutive cycles of each regimen to be included. If the time interval between claims was greater than 18 days, the regimen was considered to have been cycled every 3 weeks; if the interval was 12 to 18 days, it was considered cycled every 2 weeks, and if it was less than 12 days, it was considered a weekly dose. We selected regimens that were commonly used during the time period of the study. The selected regimens were docetaxel and cyclophosphamide administered once every 3 weeks (TC) 12, 13 ; doxorubicin and cyclophosphamideadministeredonceevery3weeks(AC) 31,32 ;docetaxel,doxorubicin, and cyclophosphamide administered once every 3 weeks (TAC) 33 ; doxorubicin and cyclophosphamide administered once every 3 weeks followed or preceded by docetaxel once every 3 weeks (AC ϩ T; patients who received fluorouracil with this regimen were also included) 34 ; dose-dense doxorubicin and cyclophosphamide administered every 2 weeks followed or preceded by paclitaxel once every 2 weeks (ddAC ϩ P) 35 ; and doxorubicin and cyclophosphamide administered once every 3 weeks followed or preceded by paclitaxel once per week (AC ϩ wP; patients who received fluorouracil with this regimen were also included). 34 Patient demographics, tumor characteristics, and treatments. From the MarketScan database, we obtained the ages, geographic regions, diagnosis years, surgery types (lumpectomy or mastectomy), hormone therapy (identified using the National Drug Code numbers in Appendix Table A4 , online only), and primary prophylaxis (PP) use of granulocyte colony-stimulating factor (G-CSF). We defined G-CSF PP use in those patients who had claims for G-CSF that occurred within 5 days after the first cycle of chemotherapy. [36] [37] [38] We also identified nonsurgery-related hospitalization claims that occurred 90 days before the beginning of chemotherapy, which served as surrogate indicators of comorbidity. From the SEER/TCR-Medicare linked database, we obtained the ages, races, geographic regions, census variables (urban/rural, education, poverty level), diagnosis years, stages (localized or regional), hormone receptor status (estrogen receptor and progesterone receptor), surgery types, and G-CSF PP use. We used the Klabunde adaptation of the Charlson comorbidity index to identify these patients' comorbidities. 39, 40 Hospitalization claims. To assess chemotherapy-related toxicities, we followed a published algorithm 41 and evaluated the rates of the first hospitalization that occurred within 6 months of chemotherapy initiation. Using Common Procedural Terminology codes, we identified eight reasons for hospitalization: neutropenia, infection, fever, thrombocytopenia, anemia, adverse effects of chemotherapy, dehydration, and delirium. We also conducted two sensitivity analyses: we calculated the chemotherapy-related hospitalization rates of the patients who received chemotherapy but were excluded from the present study (Appendix Table A2 ); we calculated the nonchemotherapyrelated hospitalization rates resulting from nonsurgical reasons (which were not part of the eight chemotherapy-related reasons).
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Statistical Analysis
We used 2 analysis to compare the proportions of patients who were hospitalized within 6 months of the initiation of each regimen. We used logistic regression models adjusted for patients' demographics, comorbidities, and tumor characteristics to compare the odds of hospitalization between patient groups. We used the Hosmer and Lemeshow test to check the goodness-of-fit of the models. P values less than .05 were considered statistically significant. The SAS software program version 9.2 (SAS Insti-tute, Cary, NC) was used to perform all data management and statistical analyses.
RESULTS
Our study population consisted of 9,327 patients identified from the MarketScan database and 3,567 patients identified from the SEER/ Abbreviations: AC, doxorubicin and cyclophosphamide; AC ϩ T, doxorubicin and cyclophosphamide followed or preceded by docetaxel; AC ϩ wP, doxorubicin and cyclophosphamide followed or preceded by weekly paclitaxel; ddAC ϩ P, dose-dense doxorubicin and cyclophosphamide followed or preceded by paclitaxel; G-CSF, granulocyte colony-stimulating factor; LND, lymph node dissection; TAC, docetaxel, doxorubicin, and cyclophosphamide; TC, docetaxel and cyclophosphamide.
‫ء‬
Unknown in 42 patients. †Received tamoxifen or an aromatase inhibitor. ‡Occurring within 90 days before initiation of chemotherapy. TCR-Medicare linked database. Each cohort's use of each regimen per year is shown in Figure 1 . In both cohorts, the percentage of patients treated with TC increased over time, and the percentage of patients treated with AC and AC ϩ T decreased over time.
The characteristics of the patients younger than age 65 years are given in Table 1 . The distribution of geographic regions varied among patients who received different regimens. The difference in hormone therapy likely reflects the rates of hormone receptor-positive disease. Among the 4,701 patients who received G-CSF PP, 96% received one dose of pegfilgrastim. The proportions of patients who received G-CSF PP were higher among those who received TAC and ddAC ϩ P (both 79%) compared with patients who received other regimens (AC, 21%; TC, 49%). The rates of hospitalization before the initiation of chemotherapy (used as surrogate indicators of comorbidity) were consistently low (4.2%) and did not differ significantly between regimens.
The characteristics of the patients younger than age 65 years are given in Table 2 . The distributions of geographic regions and race/ ethnicity varied among patients who received different regimens. Among the 2,501 patients who received G-CSF PP, 83% received one dose of pegfilgrastim. The proportions of patients who received G-CSF PP by regimen ranged from 56% (AC) to 94% (ddAC ϩ P).
The proportions of patients who were admitted to the hospital for chemotherapy-related reasons within 6 months of the initiation of chemotherapy are shown in Figure 2A . Among patients younger than age 65 years, the proportions ranged from 6.2% (ddAC ϩ P) to 10% (TAC). Only 1.2% of patients younger than age 65 years were hospitalized more than once, whereas 6.0% were hospitalized for neutropenia, fever, or infection. The hospitalization rates resulting from nonchemotherapy-related reasons ranged from 3.1% (TAC) to 6.7% (AC ϩ wP). Among patients older than age 65 years, the proportions of those who were admitted to the hospital ranged from 12.7% (TC) to NOTE. Variables with small numbers were suppressed for confidentiality reasons. Abbreviations: AC, doxorubicin and cyclophosphamide; AC ϩ T, doxorubicin and cyclophosphamide followed or preceded by docetaxel; AC ϩ wP, doxorubicin and cyclophosphamide followed or preceded by weekly paclitaxel; ddAC ϩ P, dose-dense doxorubicin and cyclophosphamide followed or preceded by paclitaxel; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; PR, progesterone receptor; TAC, docetaxel, doxorubicin, and cyclophosphamide; TC, docetaxel and cyclophosphamide.
The age categories 76-80 years and Ͼ 80 years were combined as a result of small numbers. †Regions combined as a result of small numbers: Atlanta and rural GA; CT; Detroit, MI; IA; KY; LA; NM; Seattle, WA; and UT.
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www.jco.org 24.2% (TAC); less than 5% of patients were hospitalized more than once, and 12.4% were hospitalized for neutropenia, fever, or infection. The overall hospitalization rate among patients older than age 65 years for nonchemotherapy-related reasons was 4.5%, whereas those treated with AC ϩ wP had the lowest rate, and those treated with AC ϩ T had the highest rate (5.1%). Figure 2B shows the hospitalization rates for each regimen adjusted by G-CSF PP use.
The results of the multivariable logistic regression analysis are given in Tables 3 and 4 . Patients younger than age 65 years who received TAC (odds ratio [OR], 1.74; 95% CI, 1.28 to 2.37) or AC ϩ T (OR, 1.50; 95% CI, 1.05 to 2.15) had increased odds of hospitalization for chemotherapy-related toxicities compared with those who received TC. The odds of hospitalization of patients who received other regimens did not differ significantly from those patients treated with TC. Additionally, patients who had been hospitalized within 90 days before beginning chemotherapy were 85% more likely to be hospitalized for chemotherapy-related toxicities (OR, 1.85; 95% CI, 1.35 to 2.52). In patients older than age 65 years, the regimens TAC, AC ϩ T, AC, and AC ϩ wP had odds of hospitalization for chemotherapy-related toxicities that were significantly higher than for those treated with TC. The odds of hospitalization of the patients who received ddAC ϩ P did not differ significantly from patients who received TC. Older age was also associated with higher odds of hospitalization. The Charlson comorbidity score was independently associated with hospitalization; compared with patients with a score of 0, those with a score of 1 had an OR of 1.48 (95% CI, 1.19 to 1.84), and patients with a score of Ն 2 had an OR of 2.70 (95% CI, 2.03 to 3.59).
DISCUSSION
We used medical insurance claims to compare the chemotherapyrelated hospitalization rates of patients with early-stage breast cancer who received specific chemotherapy regimens. In both cohorts, the variations in the risk of hospitalization among patients who received different regimens were significant. Overall, patients older than age 65 years had a high rate of chemotherapy-related hospitalization compared with patients younger than age 65 years. Comorbid conditions were also associated with higher rates of hospitalization in both cohorts. These results suggest that, for all age groups, the regimens TAC and AC ϩ T may be associated with a higher risk of chemotherapyrelated hospitalizations.
The durations of the chemotherapy regimens are characteristically different. For example, the TC regimen is usually given over 12 weeks, whereas the AC ϩ wP regimen is usually given over 24 weeks. These inherent differences may affect the results, given that patients who have a longer exposure to chemotherapy may have an increased likelihood of chemotherapy-related toxicities compared with patients who receive regimens of a shorter duration.
By using hospitalization claims in the SEER-Medicare linked database, Du et al 41 reported that (compared with cyclophosphamide, methotrexate, and fluorouracil) anthracycline-containing agents were associated with greater odds of chemotherapy-related toxicities in older women with breast cancer. However, taxane-based regimens were not considered in this study, and the study was not limited to adjuvant therapy. Rajan et al [36] [37] [38] have reported that G-CSF PP significantly reduces hospitalization rates in SEER-Medicare patients and improves the ability of elderly patients to complete all cycles of chemotherapy. Using the MarketScan database, Hassett et al 42 suggested that chemotherapy-related adverse events among younger patients with breast cancer (Ͻ age 64 years) may be more common than those reported by clinical trials.
A systematic review by Kuderer et al 43 of 17 randomized controlled trials that had enrolled patients with solid tumor and malignant lymphoma (age range, 15-90 years) showed that G-CSF PP reduced the risk of febrile neutropenia in patients, independently of tumor type, age, or type of G-CSF used. Using a prospective cohort of 3,760 patients with solid tumor and malignant lymphoma (39% with breast cancer), Lyman et al 44 developed a risk prediction model for neutropenic complications. Interestingly, the initial clinical trials reported that febrile neutropenia occurred in only 4% to 8% of patients who received the regimen TC. 12, 13 However, febrile neutropenia has been recently reported to occur in 24% to 30% of patients treated with TC, 45,46 placing this regimen in a high-risk category for febrile neutropenia. Because of differences in reporting toxicities, we could not directly compare the findings of our study with the adverse events described in clinical trials, which typically report toxicities according to the National Cancer Institute Common Toxicity Criteria. Noticeably, the use of G-CSF PP was not significantly protective in the multivariable regression models, which could be explained by a potential bias characteristic of observational data, in which patients more vulnerable to chemotherapy-related toxicities may be more likely to receive G-CSF PP. 36, 38 The potential limitations of the present study are inherent to retrospective claims-based research, 47 which is at best hypothesisgenerating. Administrative data do not sufficiently describe individual patients' treatment elements and outcomes and do not permit full adjustment for all key clinical confounders for hospitalization such as severity of comorbid conditions, patient's performance status, frailty, and laboratory abnormalities, which may also influence the choice of the chemotherapy regimen. Those who could not continue chemotherapy after the first cycle as a result of toxicities would be excluded from our study. Given that the intended treatment plan for each patient is unknown, it is impossible to measure the rates of early stopping of treatment for each regimen. In MarketScan, those who suffered severe toxicities that affected their employment status and possible loss of medical insurance may also have been excluded. The MarketScan database does not include tumor stage information, and patients younger than age 65 years may have been misclassified as havingearly-stagedisease.Hospitalizationdataunderrepresentschemotherapy-induced toxicities, because mild adverse events are usually managed in the outpatient setting. Long-term chemotherapy-related effects, such as cardiac toxicities associated with anthracyclines, or Abbreviations: AC, doxorubicin and cyclophosphamide; AC ϩ T, doxorubicin and cyclophosphamide followed or preceded by docetaxel; AC ϩ wP, doxorubicin and cyclophosphamide followed or preceded by weekly paclitaxel; ddAC ϩ P, dose-dense doxorubicin and cyclophosphamide followed or preceded by paclitaxel; G-CSF, granulocyte colony-stimulating factor; OR, odds ratio; TAC, docetaxel, doxorubicin, and cyclophosphamide; TC, docetaxel and cyclophosphamide.
‫ء‬
Odds ratios are adjusted for the variables listed in Table 1 in addition to the  variable region. †Occurring within 90 days before initiation of chemotherapy. Abbreviations: AC, doxorubicin and cyclophosphamide; AC ϩ T, doxorubicin and cyclophosphamide followed or preceded by docetaxel; AC ϩ wP, doxorubicin and cyclophosphamide followed or preceded by weekly paclitaxel; ddAC ϩ P, dose-dense doxorubicin and cyclophosphamide followed or preceded by paclitaxel; ER, estrogen receptor; G-CSF, granulocyte colonystimulating factor; OR, odds ratio; PR, progesterone receptor; TAC, docetaxel, doxorubicin, and cyclophosphamide; TC, docetaxel and cyclophosphamide.
debilitating neurological toxicities were beyond the scope of the present study, and we recognize that these toxicities may factor into a clinician's choice of regimen. Errors in Medicare billing and errors in capturing claims may have also occurred. Misclassification errors usually generate an underestimation of the strength of association. The eligibility criteria of the present study were designed to reduce the frequency of misclassification errors, which tend to even out over larger groups of patients. These results are from nonrandomized and nonprospective collected administrative data sets, and the toxicity results are not adjusted for the selection bias in which physicians tend to select sicker patients for less aggressive regimens; however, this bias would make these results less pronounced.
A substantial number of patients who received chemotherapy were excluded because of our selection criteria. The sensitivity analysis showed that, of the 12,506 patients younger than age 65 years who were excluded, 9.0% had been hospitalized; of the 7,354 patients older than age 65 years who were excluded, 20.8% had been hospitalized (Appendix Table A2 ). Overall, these rates are similar to those of the patients included in the present study. In addition, death information was available only for patients older than age 65 years; the percentage of these patients who died within 6 months after starting chemotherapy was less than 1% (the absolute numbers are not reported owing to confidentiality agreements).
In conclusion, these findings suggest that the TAC and AC ϩ T chemotherapy regimens may be associated with the highest risk of chemotherapy-related hospitalization in patients with early-stage breast cancer who are younger than age 65 years. In patients older than age 65 years, all regimens included in this study (aside from ddAC ϩ P) may also be associated with a higher risk of hospitalization compared with the TC regimen. 28 
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